Nucleic Acids

Nucleic Acid Therapeutics

Nucleic acids Therapeutics  encompass a vast array of approaches with a set of key considerations based on their size and mechanism of action like aptamers, antisense, small interfering RNA (siRNA), exon skipping, RNA editing. Medicinal promise of pre transcription & post- transcriptional gene silencing (PPTGS) using oligodeoxynucleotides, small interfering RNA, microRNA and other nucleic acid based molecules can be developed into effective drugs for the treatment of many common diseases that are generally responsible for a great deal of human suffering. Numerous types of cancer are known to have abnormal genes that are useful in disease states. These genes are attractive targets to approach for treatment of wide range of cancers. In different experimental systems nucleic-acid-based molecules have been shown to be very effective tools for adjusting gene expression in a sequence specific manner. Thereby they appear to be one of the most promising cancer therapeutics. They are more specialized and low toxic than conventional chemotherapy.

Relevant Conferences:      

International Conference on Amino Acids and Proteins, December 08-09, 2016 Dallas, USA ;   International Conference on Biochemistry, October 13-15, 2016 Kuala Lumpur, Malaysia ; 13^th International Conference on Nanotek and Expo, December 05-07, 2016 Phoenix, Arizona, USA; 8th International Conference on Proteomics, March 20-22, 2017 Philadelphia, USA;  2^nd International Conference on Genetic and Protein Engineering, November 14-16, 2016 Atlanta, USA; XXII International Roundtable on Nucleosides, Nucleotides and Nucleic Acids,
 on July 18-22, 2016 at Institut Pasteur, Paris, France; 5^th Zing Nucleic Acids Conference, December 02-05, 2016 Tampa, USA; 18^th International Conference on Nucleic Acids, January 07-08, 2016 Singapore; The 30^th Anniversary Symposium of the Protein Society, July 16-19, 2016 Baltimore, USA; RNA 2016, Kyoto, Japan